Stay updated on CARDINAL Trial: Bardoxolone Methyl in Alport Syndrome
Sign up to get notified when there's something new on the CARDINAL Trial: Bardoxolone Methyl in Alport Syndrome page.

Latest updates to the CARDINAL Trial: Bardoxolone Methyl in Alport Syndrome page
- CheckyesterdayChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Notably, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference5%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference4%
- Check23 days agoChange DetectedThe page has removed references to Reata as a subsidiary of Biogen and updated the date from February 2, 2024, to June 11, 2025.SummaryDifference3%
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.3%
- Check38 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check67 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
Stay in the know with updates to CARDINAL Trial: Bardoxolone Methyl in Alport Syndrome
Enter your email address, and we'll notify you when there's something new on the CARDINAL Trial: Bardoxolone Methyl in Alport Syndrome page.